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LETTERS TO THE EDITORExome Sequencing in Brown-
Vialetto-Van Laere Syndrome
To the Editor: Brown-Vialetto-van Laere syndrome (BVVL
[MIM 211530]) is a rare, progressive, childhood neurode-
generative disease that is characterized by pontobulbar
palsy, sensorineural hearing loss, and respiratory problems.
BVVL is clinically heterogeneous, presenting as early as the
neonatal period and as late as the third decade of life.1
BVVL has a prominent familial component, consistent
with an autosomal-recessive mode of inheritance, in all
but one family reported. The genetic cause of BVVL was
until recently unknown; therefore, we read with interest
the recent article by Green and colleagues that described
mutations of C20orf54 (MIM 613350) as the underlying
cause of BVVL.2 We congratulate the authors on this
exciting new finding.
At the time of publication by Green and colleagues, we
were working on the identification of the genetic cause of
BVVL, using predominantly whole-exome sequencing but
also whole-genome sequencing. We had performed
sequence enrichment for the exome using the SureSelect
Human Exome Kit (Agilent Technologies), followed by
second-generation sequencing on a GAIIx (Illumina) in
two siblings and two unrelated patients with BVVL. In
addition, we had performed exome enrichment and
sequencing on one sample from family 2008, using
a service from Roche which used NimbleGen array
capture and 454 sequencing. Sequence alignment, quality
control, and variant calling was performed with BWA,3
SAMTools,4 the Genomic Analysis Toolkit (GATK),5 and
Picard. When necessary, sequences were viewed with the
use of IGV.
DNA from human subjects was collected after written,
informed consent was given, and this study was approved
by the institutional review board of the National Institute
on Aging. Variants were identified with GATK’s SingleSam-
pleGenotyper and IndelGenotyper tools. The single-nucle-
otide variants were then filtered for the removal of
low-quality variant calls with GATK’s VariantFiltration-
Walker tool, with filtering based on the LodThreshold,
FisherStrand, ClusteredSnps, AlleleBalance, and IndelArti-
fact attributes. Prior to variant calling, each lane of exome
and genome sequence data was aligned with the use of
BWA. Samtools and Picard were used to convert, sort,
and index the aligned data files. The sequence quality
scores were recalibrated with GATK. Picard was then used
to identify and remove duplicate reads from each lane
and then merge the multiple lanes of sequencing data
per patient.
Because we believed that underlying genetic mutation(s)
causing BVVL was likely to be extremely rare, all iden-
tified variants were then filtered against dbSNP and 1000The AmericGenomes, removing all previously reported variants.
Restricting the variants to 937 nonsynonymous alter-
ations detected in at least one of the four samples, we
selected only those changes that were homozygous, or
when a variant was heterozygous, an additional heterozy-
gous variant was present in the same gene, in the same
sample. This resulted in a sample-specific list of 37 genes
with 39 homozygous nonsynonymous mutations and 48
genes with 140 compound-heterozygous nonsynony-
mous changes. We then compared these gene lists across
samples and identified genes present in the affected
siblings and at least one of the two other BVVL patients.
This resulted in a list of eight genes, three of which con-
tained a large number of variants, and we see a large
number of previously unreported changes consistently in
these transcripts across exome studies, suggesting that
these variants are likely an artifact of the methodology
(CTBP2 [MIM 602619], OR4C3 and CDC27 [MIM
116946]; unpublished data), most likely because of
sequencing error, a systematic artifact of the selection
process, or an error in the underlying alignment. The re-
maining five genes were our primary candidates for BVVL:
LOC100130581, KIR2DL3 (MIM 604938), ANKRD20B,
C20orf54, and USP17L2.
At this point we read Green and colleagues’ work. We es-
tablished that patient 2008-410 (II:2) in our study, corre-
sponds to case 4 in the study by Green et al. Notably,
although we also found the c.639C>G (p.Y213X; nucleo-
tide sequence numbering is based on sequence
NM_033409) mutation in C20orf54 (NM_033409.3) re-
ported by Green et al., in our exome-sequencing data, we
observed this as a heterozygous mutation, rather than as
a homozygous mutation as reported. Further, in this
sample and in the DNA sample from the affected sibling,
exome sequencing identified an additional rare heterozy-
gous variant not reported by Green and colleagues,
c.211G>A (p.E71K). To establish whether our observations
were an artifact of the enrichment or of the second-gener-
ation sequencing process, we performed additional Sanger-
based sequencing. This confirmed that both variants were
present in both affected siblings as heterozygous changes
(Figure 1). Analysis of DNA from the parents of 2008-410
(II:2) and 2008-411 (II:1) demonstrated that these two vari-
ants were indeed compound heterozygotes, the c.639C>G
(p.Y213X) variant being inherited from the mother (I:1)
and the c.211G>A (p.E71K) variant being inherited from
the father (I:2) (Figure 1).
In sample 48111 (IV:1) from family DZ, exome
sequencing revealed a rare homozygous c.82C>A
(p.P28T) variant in C20orf54, and this was confirmed by
Sanger sequencing (Figure 1). It was subsequently
confirmed that this alteration segregates with disease in
an affected niece (V:1) and an affected sibling (IV:2)
(Figure 1). We failed to identify a rare nonsynonymousan Journal of Human Genetics 87, 567–570, October 8, 2010 567
Figure 1. C20orf54Mutations in Patients
with BVVL
(A) Heterozygous c.211G>A (p.E71K)
mutation carried by both affected children
(2008-410, II:2 and 2008-411, II:1) and the
patients’ father (I:2) but not by the
patients’ mother (I:1).
(B) Heterozygous c.639C>G (p.Y213X)
mutation carried by both affected siblings
and their mother (2008-410, II:2;
2008-411, II:1; and I:1) but not by the
father (I:2).
(C) Homozygous c.82C>A (p.P28T) muta-
tion carried by patient 48111 (IV:1) from
family DZ.
(D) Pedigrees of families DZ and 2008/13,
probands indicated by arrows.variant in C20orf54 in sample HH, the proband from
a recessive family with typical childhood-onset BVVL, sug-
gesting genetic heterogeneity in this disorder. However,
the family was not informative enough to be useful for
linkage analysis, and therefore we cannot exclude the
possibility that we have missed a mutation.
Family DZ, which originated from Eastern Turkey,
shows multiple consanguinity and has a total of three
affected children with BVVL. Clinical features were iden-
tical, but there was over 20 yrs difference in the age at
onset, with one case available for postmortem examina-
tion. The proband (IV:1) developed normally until she
presented with acute respiratory distress, stridor, and
paralysis of vocal cord abduction, requiring ventilation.
She later developed cranial nerve palsies with ophthal-
moplegia, dysarthria, dysphagia, tongue fasciculation,
facial weakness, and weakness and wasting of the limbs.
She died at the age of 8 yrs from respiratory failure. A
postmortem examination was carried out, which revealed
replacement gliosis of the cranial nuclei, particularly at
the bulbo-pontine level, but only mild anterior horn
cell involvement. The proband’s affected sister (IV:2)
developed hearing loss at the age of 10 yrs over a matter
of months. In the following years she developed features
identical to those of her deceased older sister, with
progressive bulbar palsy, dysarthria, dysphagia, tongue
fasciculation, facial weakness, weakness and wasting of
the limbs, and breathing problems. Investigations re-
vealed a motor neuronopathy and axonal degeneration
on a nerve biopsy. She died at the age of 29 yrs from
respiratory failure. A niece of the proband (V:1) is also568 The American Journal of Human Genetics 87, 567–570, October 8, 2010clinically affected but is in the early
stages of the disease. She has hearing
problems and cranial nerve palsies.
In family DZ the p.P28T mutation
segregated with the disease as
a homozygous trait and was not
present in controls.
Family 2008 is from the United
States, with European and Asianancestry. The proband (II:1) developed normally until
16 mo of age, when she was diagnosed with progressive
bulbar palsy. Over the next 17 mo she developed multiple
cranial nerve palsies, beginning with bilateral vocal fold
paralysis necessitating tracheostomy, facial and pharyn-
geal muscle weakness necessitating percutaneous endo-
scopic gastrostomy, hearing loss, and weakness and
wasting of her limbs distally and of her neck muscles,
requiring a brace. She was a bright child and was able to
use sign language to communicate with her family. She
became ventilator dependent in the last few months of
her life and passed away from pneumonia, a complication
of her tracheostomy. The brother (II:2) of the proband was
born with transposition of the great vessels, requiring
surgery at birth. He was well until the age of 9 mo, when
he developed a unilateral ptosis that had been intermittent
since birth but became permanent at this time. At this time
he had abnormal bilateral auditory evoked potentials, and
at the age of 12 mo he developed stridor due to bilateral
adductor vocal fold paralysis. He was stable for 5 mo,
babbling, playing, starting to stand and walk, and eating
without difficulty or aspiration, but he developed an over-
active gag reflex and over the next few months developed
problems very similar to those of his sister and died of
respiratory failure.
In summary we report accurate mutation detection of
disease-causing mutations for BVVL by exome sequencing.
We describe a compound heterozygous c.639C>G/
c.211G>A (p.Y213X/p.E71K) mutation in a family previ-
ously reported to have disease caused by a homozygous
p.Y213X mutation, and we report a p.P28T mutation,
absent from dbSNP and 1000 Genomes data, that we
propose to be a cause of BVVL.We also describe the clinical
and genetic heterogeneity that is present in BVVL.
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To the Editor: Johnson et al. report that a secondmutation
in C20orf54 (MIM *613350) is seen in their BVVLS family
‘‘2008,’’ which appears to be the same individual as our
‘‘case 4,’’1 implying that this patient is a compound hetero-
zygote (p.E71K and p.Y213X) rather than homozygous for
Y213X. Upon reexamination of the sequence traces, even
with the benefit of hindsight, we still see a homozygous
change at Y213X, although we do see a heterozygous
change at E71K. We concur that this patient is most likely
a compound heterozygote on the basis of the results of
Johnson et al. This clearly demonstrates the advantage of
testing additional family members, including parents
whom we did not have access to at the time of paper
submission.
We can confirm that we have also identified the homo-
zygous mutation p.P28T in a sample provided to us by
H. Houlden, which appears to be the second BVVLSpatient reported by Johnson et al. (sample 48111). This
result was not published in our report.1
We read with interest the exome-sequencing data the
authors provide in their Letter. Before we submitted our
paper, Dr. Singleton, upon learning that we had identified
mutations in our BVVLS patients, provided us with a short
list of 364 variants in 223 candidate genes from his study.
Neither c20orf54, nor the other four genes mentioned in
their letter appeared in this short list. The approach of
whole-exome sequencing for determining causative muta-
tions in rare monogenic disorders is one of the many
exciting developments of next-generation sequencing.2
It is currently still a very expensive, sledgehammer
approach, which will undoubtedly become more cost
effective in the near future. Some of the pitfalls demon-
strated by Johnson et al. may also be ameliorated by tech-
nical improvements. Notably, sequencing several patients,
filtering by dbSNP, and shortlistingmutations that occur in
all patients may yield confusing results if, as in thean Journal of Human Genetics 87, 567–570, October 8, 2010 569
